Selected research
Industry Research
Anti Obesity Drugs Industry Research Report 2026
Market perspective
The global Anti Obesity Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti Obesity Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti Obesity Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti Obesity Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti Obesity Drugs include Wanhan Pharma, ZENIN Biotechnology, Teva, Novartis, Roche, Lunan Pharma, Eli Lilly, VIVUS and Pharscin Pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti Obesity Drugs market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti Obesity Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti Obesity Drugs Market by Company
Wanhan Pharma
ZENIN Biotechnology
Teva
Novartis
Roche
Lunan Pharma
Eli Lilly
VIVUS
Pharscin Pharma
Novo Nordisk
Lupin Laboratories
iNova Pharmaceuticals
Hypera Pharma
GlaxoSmithKline
Alvogen
Anti Obesity Drugs Segment by Type
Injection
Oral
Anti Obesity Drugs Segment by Application
Hospital
Retail Pharmacy
Other
Anti Obesity Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti Obesity Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti Obesity Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti Obesity Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti Obesity Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Wanhan Pharma
- ZENIN Biotechnology
- Teva
- Novartis
- Roche
- Lunan Pharma
- Eli Lilly
- VIVUS
- Pharscin Pharma
- Novo Nordisk
- Lupin Laboratories
- iNova Pharmaceuticals
- Hypera Pharma
- GlaxoSmithKline
- Alvogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti Obesity Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Injection
- 2.2.3 Oral
- 2.3 Anti Obesity Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Anti Obesity Drugs Breakdown Data by Type
- 3.1 Global Anti Obesity Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Anti Obesity Drugs Forecasted Market Size by Type (2027-2032)
4 Anti Obesity Drugs Breakdown Data by Application
- 4.1 Global Anti Obesity Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Anti Obesity Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti Obesity Drugs Market Perspective (2021-2032)
- 5.2 Global Anti Obesity Drugs Growth Trends by Region
- 5.2.1 Global Anti Obesity Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti Obesity Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Anti Obesity Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Anti Obesity Drugs Market Dynamics
- 5.3.1 Anti Obesity Drugs Industry Trends
- 5.3.2 Anti Obesity Drugs Market Drivers
- 5.3.3 Anti Obesity Drugs Market Challenges
- 5.3.4 Anti Obesity Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti Obesity Drugs Players by Revenue
- 6.1.1 Global Top Anti Obesity Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Anti Obesity Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti Obesity Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti Obesity Drugs Head Office and Area Served
- 6.4 Global Anti Obesity Drugs Players, Product Type & Application
- 6.5 Global Anti Obesity Drugs Manufacturers Established Date
- 6.6 Global Anti Obesity Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti Obesity Drugs Market Size (2021-2032)
- 7.2 North America Anti Obesity Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti Obesity Drugs Market Size by Country (2021-2026)
- 7.4 North America Anti Obesity Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti Obesity Drugs Market Size (2021-2032)
- 8.2 Europe Anti Obesity Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti Obesity Drugs Market Size by Country (2021-2026)
- 8.4 Europe Anti Obesity Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti Obesity Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Anti Obesity Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti Obesity Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti Obesity Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti Obesity Drugs Market Size (2021-2032)
- 10.2 South America Anti Obesity Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti Obesity Drugs Market Size by Country (2021-2026)
- 10.4 South America Anti Obesity Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti Obesity Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Anti Obesity Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti Obesity Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti Obesity Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Wanhan Pharma
- 12.1.1 Wanhan Pharma Company Information
- 12.1.2 Wanhan Pharma Business Overview
- 12.1.3 Wanhan Pharma Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.1.4 Wanhan Pharma Anti Obesity Drugs Product Portfolio
- 12.1.5 Wanhan Pharma Recent Developments
- 12.2 ZENIN Biotechnology
- 12.2.1 ZENIN Biotechnology Company Information
- 12.2.2 ZENIN Biotechnology Business Overview
- 12.2.3 ZENIN Biotechnology Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.2.4 ZENIN Biotechnology Anti Obesity Drugs Product Portfolio
- 12.2.5 ZENIN Biotechnology Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.3.4 Teva Anti Obesity Drugs Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.4.4 Novartis Anti Obesity Drugs Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.5.4 Roche Anti Obesity Drugs Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Lunan Pharma
- 12.6.1 Lunan Pharma Company Information
- 12.6.2 Lunan Pharma Business Overview
- 12.6.3 Lunan Pharma Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.6.4 Lunan Pharma Anti Obesity Drugs Product Portfolio
- 12.6.5 Lunan Pharma Recent Developments
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Information
- 12.7.2 Eli Lilly Business Overview
- 12.7.3 Eli Lilly Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.7.4 Eli Lilly Anti Obesity Drugs Product Portfolio
- 12.7.5 Eli Lilly Recent Developments
- 12.8 VIVUS
- 12.8.1 VIVUS Company Information
- 12.8.2 VIVUS Business Overview
- 12.8.3 VIVUS Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.8.4 VIVUS Anti Obesity Drugs Product Portfolio
- 12.8.5 VIVUS Recent Developments
- 12.9 Pharscin Pharma
- 12.9.1 Pharscin Pharma Company Information
- 12.9.2 Pharscin Pharma Business Overview
- 12.9.3 Pharscin Pharma Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.9.4 Pharscin Pharma Anti Obesity Drugs Product Portfolio
- 12.9.5 Pharscin Pharma Recent Developments
- 12.10 Novo Nordisk
- 12.10.1 Novo Nordisk Company Information
- 12.10.2 Novo Nordisk Business Overview
- 12.10.3 Novo Nordisk Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.10.4 Novo Nordisk Anti Obesity Drugs Product Portfolio
- 12.10.5 Novo Nordisk Recent Developments
- 12.11 Lupin Laboratories
- 12.11.1 Lupin Laboratories Company Information
- 12.11.2 Lupin Laboratories Business Overview
- 12.11.3 Lupin Laboratories Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.11.4 Lupin Laboratories Anti Obesity Drugs Product Portfolio
- 12.11.5 Lupin Laboratories Recent Developments
- 12.12 iNova Pharmaceuticals
- 12.12.1 iNova Pharmaceuticals Company Information
- 12.12.2 iNova Pharmaceuticals Business Overview
- 12.12.3 iNova Pharmaceuticals Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.12.4 iNova Pharmaceuticals Anti Obesity Drugs Product Portfolio
- 12.12.5 iNova Pharmaceuticals Recent Developments
- 12.13 Hypera Pharma
- 12.13.1 Hypera Pharma Company Information
- 12.13.2 Hypera Pharma Business Overview
- 12.13.3 Hypera Pharma Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.13.4 Hypera Pharma Anti Obesity Drugs Product Portfolio
- 12.13.5 Hypera Pharma Recent Developments
- 12.14 GlaxoSmithKline
- 12.14.1 GlaxoSmithKline Company Information
- 12.14.2 GlaxoSmithKline Business Overview
- 12.14.3 GlaxoSmithKline Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.14.4 GlaxoSmithKline Anti Obesity Drugs Product Portfolio
- 12.14.5 GlaxoSmithKline Recent Developments
- 12.15 Alvogen
- 12.15.1 Alvogen Company Information
- 12.15.2 Alvogen Business Overview
- 12.15.3 Alvogen Revenue in Anti Obesity Drugs Business (2021-2026)
- 12.15.4 Alvogen Anti Obesity Drugs Product Portfolio
- 12.15.5 Alvogen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst